NSCLC,CD200RCD11b+CD4+CTLs

Mingjie Lin1, Di Chen2, Zheyu Shao1

  • 1Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310009, China; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310009, China.

Cell reports
|February 14, 2024
PubMed
概括

CD11b+CD4+细胞毒性T淋巴细胞 (CTLs) 在非小细胞肺癌 (NSCLC) 中被确定. 向CD200可重振这些功能障碍的CTLs,提供一个有前途的NSCLC免疫疗法策略.